RARE - Ultragenyx down 13% following acquisition of Angelman syndrome biotech

• Investors don't appear happy with Ultragenyx Pharmaceutical's ( NASDAQ: RARE ) closing bell announcement Monday that it would be acquiring GeneTx Biotherapeutics , which is solely focused on its Angelman syndrome drug GTX-102.
• Volume in Ultragenyx is much higher than normal Tuesday. With more than 3.8M shares that have traded hands as of 245p ET, that's nearly seven times the daily average.
• Ultragenyx ( RARE ) is shelling out $75M upfront to acquire GeneTx.
• Interim data from a phase 1/2 trial showed meaningful improvement in clinical disease with GTX-102.
• Read Seeking Alpha contributor's Avisol Capital Partners' investment thesis for Ultragenyx ( RARE ).

For further details see: